Key result
Concurrent Type 2 diabetes in patients with coronary artery disease was associated with lower serum adiponectin levels compared to CAD alone.
Observational (n=198)
Serum adiponectin levels are significantly reduced in patients with both coronary artery disease and type 2 diabetes compared to those with CAD alone, which may be driven by increased insulin resistance and inflammation.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of adiponectin testing; leaves open its role as biomarker or target in CAD with diabetes.
BACKGROUND: Adiponectin, an adipocyte-derived hormone, is implicated in diabetes mellitus type 2 and atherosclerosis. The study was designed to investigate whether serum adiponectin levels in patients with both coronary artery disease (CAD) and diabetes mellitus type 2 (T2DM) are lower than in patients with CAD alone and control subjects. OBJECTIVES: In this present study, we measured serum adiponectin levels in consecutive CAD patients with and without T2DM and investigated whether decreased adiponectin is associated with risk factors of CAD. MATERIALS AND METHODS: The study included 198 subjects, 138 patients with CAD (72 of whom had both CAD and T2DM), and 60 control subjects. We measured serum adiponectin, interleukin-6 (IL-6) and insulin by ELISA. In addition, Lipid profile, glucose and anthropometrical measurements were performed in all subjects. RESULTS: The results revealed significant difference in serum adiponectin levels between patients with CAD+T2DM and patients with CAD alone (3.80 ± 1.52 vs. 5.25 ± 2.35, P = 0.007), between patients with CAD and control (5.25 ± 2.35 vs. 7.04 ± 3.32, P = 0.001), and between patients with CAD + T2DM and control (3.80 ± 1.52 vs. 7.04 ± 3.32, P < 0.001). Serum adiponectin level was significantly higher in women in contrast to men (5.97 ± 3.15 vs. 4.62 ± 2.81 µg/ml, P = 0.002). Serum adiponectin levels were correlated significantly with insulin (r = -0.178, P = 0.013), total cholesterol (r = -0.313, P < 0.001), low density lipoprotein (r = -0.154, P = 0.016), body mass index (r = -0.171, P = 0.016), glucose (r = -0.202, P = 0.006), HOMA-IR (r= -0.251, P = 0.001), and IL-6 levels (r = -0.321, P = 0.001). Adiponectin was correlated positively only with high density lipoprotein (r = 0.389, P < 0.001). CONCLUSIONS: It is speculated that increased insulin resistance and increase in other adipokines such as IL-6 may contribute to the decreased serum levels of adiponectin in patients with both CAD and T2DM.
No takes yet. Share an insight, caveat, or question.
Mohammadzadeh et al. (2014) conducted an observational in Coronary Artery Disease and Type 2 Diabetes Mellitus (n=198). Concurrent Type 2 Diabetes Mellitus vs. CAD alone and control subjects was evaluated on Serum adiponectin levels (p=0.007). Concurrent Type 2 diabetes in patients with coronary artery disease was associated with lower serum adiponectin levels compared to CAD alone.
Synapse has enriched 10 related papers. Consider them for comparative context: